Compare Cognizant Technology Solutions Corp (CTSH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Sanofi SA — how do they compare? Cognizant Technology Solutions Corp trades at $59.25 (market cap $27.03B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.5× Cognizant Technology Solutions Corp's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Sanofi SA for 94 Days on average.
| CTSH | SNY | |
|---|---|---|
Market Cap | $27.03B | $95.18B |
Volume | 9,883,888 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $86.70 | $52.34 |
52-Week Low | $38.73 | $39.51 |
Typical Hold Time | 57 Days | 94 Days |
Enterprise Value | $28.08B | $114.48B |
Dividend Yield | 2.2% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.20, up 3.73% today, with a bullish technical signal from moving averages and support at $56. The stock shows solid fundamentals with a P/E of 12.88, net income margin of 10.26%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven initiatives and strong employer recognition, supporting positive sentiment.
CTSH presents a favorable risk-reward profile with a consensus price target of $64.25 offering ~8.5% upside. Key opportunities include AI integration and stable cash flow, while risks involve IT spending pressures and competitive threats. Analyst consensus is balanced between Buy and Hold ratings, reflecting cautious optimism amid industry headwinds.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
